Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy

James B Brock; Peyton Herrington; Melissa Hickman; Aubri Hickman

doi:10.1093/cid/ciad511

Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy

Clin Infect Dis. 2024 Jan 25;78(1):122-124. doi: 10.1093/cid/ciad511.

Authors

James B Brock¹, Peyton Herrington¹, Melissa Hickman¹, Aubri Hickman¹

Affiliation

¹ Department of Medicine, Division of Infectious Diseases, University of Mississippi Medical Center . Jackson, Mississippi, USA.

PMID: 37740255
DOI: 10.1093/cid/ciad511

Abstract

We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.

Keywords: HIV; therapeutics.

MeSH terms

Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
Diketopiperazines*
HIV Infections* / drug therapy
Humans
Pyridones*
Rilpivirine / therapeutic use

Substances

cabotegravir
Rilpivirine
Anti-HIV Agents
Anti-Retroviral Agents
Pyridones
Diketopiperazines